Abstract
The aim of the study was to investigate the efficacy and safety of the drug Cetrilev for treatment children withallergic rhinitisand asthma. Methods. 60 children aged 6–14 years with persistent allergic rhinitisand asthma were included in this study. All the children were divided into two groups: group 1(32 children) and group 2 (29 children). Group1 of children were given Cetrilev («Euro Lifecare LTD») in addition to the standard treatment, with a dosage of 1 tablet (5 mg) per day for 4 weeks. Children from the comparison group 2 received only the standard treatment. As a standard treatment of Asthma, Montelukast 5 mg was given once daily in the evening. To evaluate the effectiveness of all the children held a score of symptoms of allergic rhinitis and asthma, spirometry, nasal cytology, asthma control testing. Results. The study have shown that the inclusion of the drug Cetrilev in therapy children with allergic rhinitis and asthma had a positive effect on symptoms such as rhinitis and asthma. Children of the group1had significant regression of symptoms of allergic rhinitis , reduction of inflammatory changes in the mucosa of the upper respiratory tract, improvement of lung function. Conclusion: Therapeutic effect of the drug Cetrilev is associated with anti-allergic and anti-inflammatory effects. The absence of side effects, good tolerability of this drug can be recommended for its treatment of allergic rhinitis in children of school age with asthma. Key words: allergic rhinitis,asthma, treatment, levocetirizine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
